This clinical trial is focused on studying a condition called anemia that is associated with a type of blood disorder known as myeloproliferative neoplasm-associated myelofibrosis. This condition often requires patients to receive regular red blood cell transfusions to manage their symptoms. The study is testing a treatment called luspatercept, also known by its code name ACE-536 (BMS-986346), to see if it can help reduce the need for these transfusions. Luspatercept is given as a solution for injection under the skin.
The purpose of the study is to compare the effectiveness and safety of luspatercept with a placebo in adults who are already receiving a type of medication called a JAK2 inhibitor as part of their standard treatment. Participants in the study will receive either luspatercept or a placebo, and their progress will be monitored over a period of time to see if they can become free from needing red blood cell transfusions for at least 12 weeks.
Throughout the study, participants will continue their usual treatment with the JAK2 inhibitor while receiving the study medication. The trial aims to provide valuable information on whether luspatercept can offer a significant benefit in managing anemia in patients with myelofibrosis, potentially improving their quality of life by reducing the frequency of blood transfusions needed.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Hungary 
Ireland 
Italy 
Poland 
Romania 
Spain